Riskpilot← Back to searchSign inGet full accessVarCT Diagnostics ApS
APSActiveCVR 38733567Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 20177 employees
Revenue 2024
DKK 3,4M
+674% vs 2023
EBITDA margin
15.4%
+125% vs 2023
Equity ratio
74.1%
Financial strength
Net profit 2024
DKK 779K
+147% vs 2023
| Revenue | DKK 3,4M | +674% |
| EBITDA | DKK 528K | +125% |
| Net profit | DKK 779K | +147% |
| Total assets | DKK 5,7M | -11% |
| Equity | DKK 4,2M | +23% |
| Employees | 7 | — |
Legal name
VarCT Diagnostics ApS
CVR number
38733567
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20. juni 2017
Share capital
DKK 56.250
Employees
7 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem eller en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er, direkte eller via besiddelse af kapitalandele i andre selskaber, at drive virksomhed inden for kræftdiagnosticering og -bekæmpelse samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
Address
Nordre Fasanvej 215
Email
salanti@sund.ku.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -617 | -472 | -2.021 | 1.175 | -483 | 89 | 442 | 3.425 |
| Staff expenses | -0 | -1.360 | -1.645 | -1.832 | -1.316 | -2.384 | -2.592 | -2.897 |
| EBITDA | -617 | -1.833 | -3.666 | -657 | -1.799 | -2.296 | -2.150 | 528 |
| Depreciation & amort. | -76 | -218 | -348 | -346 | -334 | -260 | -130 | -0 |
| EBIT | -693 | -2.051 | -4.014 | -1.003 | -2.133 | -2.555 | -2.280 | 528 |
| Net financials | -9 | -71 | -45 | -11 | -8 | 22 | 214 | 251 |
| Profit before tax | -702 | -2.121 | -4.058 | -1.014 | -2.141 | -2.533 | -2.066 | 779 |
| Tax | -261 | -354 | -837 | -253 | -394 | -603 | -421 | -0 |
| Net profit | -442 | -1.767 | -3.221 | -761 | -1.746 | -1.930 | -1.645 | 779 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 7.227 | 14.182 | 12.004 | 10.266 | 10.562 | 6.884 | 6.405 | 5.668 |
| Equity | 7.041 | 12.724 | 9.503 | 8.742 | 6.996 | 5.065 | 3.421 | 4.200 |
| Long-term debt | 0 | 0 | 69 | 200 | 156 | 156 | 156 | 172 |
| Short-term debt | 186 | 1.276 | 2.431 | 1.324 | 3.410 | 1.662 | 2.828 | 1.296 |
| Total debt | 186 | 1.276 | 2.501 | 1.524 | 3.566 | 1.818 | 2.984 | 1.469 |
EBITDA margin
15.4%
This company
15.8%
Market median
+3% vs market
20172024
Equity ratio
74.1%
This company
38.2%
Market median
+94% vs market
20172024
Return on equity
18.6%
This company
18.4%
Market median
+1% vs market
20172024
Net profit margin
22.7%
This company
8.1%
Market median
+180% vs market
20172024
Asset turnover
0.60×
This company
1.12×
Market median
-46% vs market
20172024
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-06-20 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AE Management | Management | 2017 | — | — |
UA Management | Management | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
VAR2 PHARMACEUTICALS ApS | Company | 66.7% | 66.7% | 2018 |
| Individual | 20.0% | 20.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ONCOMAL ApS
VarCT Diagnostics ApS Board members of VarCT Diagnostics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ali El-Salanti | Management | 0 companies |
| Ulf Andreas Linderoth Norlin | Management | 0 companies |
| Poul Henrik Bredahl Sorensen | Board of Directors | 0 companies |
| Peter Schröcksnadel | Board of Directors | 0 companies |
| Mads Daugaard | Chairman | 0 companies |
| Thor Grundtvig Theander | Board of Directors | 0 companies |
| Josef Rainer | Board of Directors | 0 companies |